The UK Competition Authority finds that a merger between two hearing implant providers could lead to higher prices for the national health service, reduced quality and slower innovation for UK patients who rely on hearing aids (Cochlear / Oticon)

Hearing implants merger could mean worse deal for NHS and patients* The merger of 2 leading providers of hearing implants could lead to higher prices for the NHS, and reduced quality and slower innovation for UK patients who rely on these life-changing devices. The Competition and Markets Authority (CMA) is concerned that Cochlear’s proposed purchase of Oticon Medical – the hearing implant division of Demant –would have a negative impact on patients who

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • United Kingdom’s Competition Authority (CMA) (London)

Quotation

UK Competition Authority, The UK Competition Authority finds that a merger between two hearing implant providers could lead to higher prices for the national health service, reduced quality and slower innovation for UK patients who rely on hearing aids (Cochlear / Oticon), 6 December 2022, e-Competitions December 2022, Art. N° 109846

Visites 65

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues